Clinical trial
The Efficacy and Safety of Sintilimab in Combination With Multimodal Radiotherapy in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma After Multi-line Treatment (Including Immunotherapy)
NCT04917770 is registered in ClinicalTrials.gov with West China Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- The Efficacy and Safety of Sintilimab in Combination With Multimodal Radiotherapy in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma After Multi-line Treatment (Including Immunotherapy)
- Lead sponsor
- West China Hospital
- Phase
- Phase 2
- Overall status
- Unknown status
- Start date
- June 30, 2021
- Completion date
- June 30, 2024
- Enrollment
- 28 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.